Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-IV criteria for pathological gambling~* Meets DSM-IV and SCID criteria for alcohol abuse or dependence~* Medically healthy~Exclusion Criteria:~* History of schizophrenia, schizoaffective disorder, or bipolar disorder~* Current diagnosis of substance abuse or dependence, other than alcohol or nicotine~* Current major depression~* Currently suicidal~* History of non-response to an adequate trial of sertraline, defined as 200 mg per day of sertraline for at least a 4-week period~* Previous treatment with relapse prevention therapy for pathological gambling or alcohol dependence within the 3 months prior to study entry~* Requires treatment with psychotropic medication~* Unwilling to consent to a drug-free period, according to the following: 2 weeks of abstinence from antidepressant drugs, other than fluoxetine, buspirone, lithium, anticonvulsants, barbiturates, opiates, or benzodiazepines; 4 weeks of abstinence from clonazepam; 5 weeks of abstinence from fluoxetine~* Clinically significant disorder, including kidney, pulmonary, cerebral vascular, cardiovascular, gastrointestinal, and endocrine disorders~* Abnormal laboratory tests~* Abnormal electrocardiogram~* Pregnant or breastfeeding~* Unwilling to use an adequate method of contraception for the duration of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo and Relapse Prevention (Type: PLACEBO_COMPARATOR): Patients will be treated with Relapse Prevention Therapy plus placebo
- Sertraline and Relapse Prevention (Type: ACTIVE_COMPARATOR): Patients will be treated with Relapse Prevention Therapy plus Sertraline.

Based on this trial design, predict the completion outcome and termination type (if applicable).